The GLP-1 class carries the largest safety evidence base any obesity treatment has ever had — well over 142,000 clinical-trial participants across the flagship programs, plus years of post-market surveillance on millions of users. That depth allows something rare: a genuine safety comparison across the class rather than a generic warnings list. Here's what the accumulated data shows.
| Semaglutide | Tirzepatide | Liraglutide | Oral agents (o. sema / orforglipron) | |
|---|---|---|---|---|
| GI side effects (nausea etc.) | Common, dose-dependent, usually transient | Common; comparable family | Common; daily dosing spreads exposure | Common; class-typical |
| Long-horizon outcomes data | Deepest: SELECT (~4 yrs, 17,604 pts) | Growing; large program | Longest market history in class | Newest; accruing |
| Signature cautions | Class warnings* | Class warnings* | Class warnings* | Class warnings*; o. sema absorption rules |
| Discontinuation for side effects | Minority of trial participants | Similar order | Similar order | Similar order |
What the Class Shares
Safety differences within the class are smaller than marketing suggests. Across every agent: gastrointestinal effects dominate (nausea, constipation, diarrhea — typically worst during titration and improving after), and the serious-but-rare tier is a shared list — pancreatitis, gallbladder events, and the boxed thyroid warning derived from rodent findings, which is why personal/family history of medullary thyroid carcinoma or MEN2 contraindicates the whole class. Slowed gastric emptying also matters before anesthesia — surgeons and anesthesiologists now routinely ask.
Where the Profiles Genuinely Differ
- Depth of evidence is semaglutide's safety feature. SELECT's ~four-year, 17,604-patient cardiovascular trial produced not just efficacy but an unusually long, clean safety record — including a mortality benefit. No other agent matches that horizon yet.
- Tirzepatide's higher efficacy, similar tolerability is its quiet safety story: SURMOUNT-era data showed the bigger weight effect without a proportionally worse side-effect burden.
- Liraglutide's differences are practical: daily injections and an older evidence base — its safety record is long, its results modest.
- The new pills are the actuarial youngsters. Nothing alarming has emerged, and orforglipron's Phase 3 program was large — but "approved in 2026" simply means fewer patient-years on the books. Reasonable people weight that.
Reading Safety Like an Adult
Screening Is the Whole Ballgame
Every caution above is exactly why real prescriber screening — history, contraindications, medication review — isn't red tape. Programs with genuine clinical intake are the ones taking the safety data seriously:
Sesame Care
Brand-name route — Rybelsus, oral Wegovy, and injectable brand GLP-1s via low-cost doctor visits.
Flat-rate visits · brand-name FDA-approved medications only
- FDA-approved brand-name medications only
- Fast video visits in most states
- Pairs well with $199 direct-pay channels
RxSpan MD
Physician-led telehealth program with ongoing dose management.
Program pricing shown at checkout
- Physician-led care
- Ongoing dose management
- US pharmacy fulfillment
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Visit RxSpan MD Paid linkCare Bare Rx
Telehealth GLP-1 program with both injectable and oral options in intake.
Pricing shown after provider intake
- Injectable and oral options
- Licensed US providers
- Quick eligibility check
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Visit Care Bare Rx Paid linkBottom Line
No medication class this new has ever been this thoroughly watched. The data says the honest sentence plainly: well-screened patients face mostly transient GI effects, rare serious risks their provider screens for, and — per the largest trial — better survival odds treated than not.
Last updated August 2026. This is general information, not a substitute for prescriber screening of your individual risk factors.
See the Full Comparison Grid
Every provider and channel we track — price, format, and what's included — side by side.
Compare All ProvidersMore Comparisons
The Compounded Market in 2026: State of Play
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All prescription medications discussed require evaluation by a licensed healthcare provider. Always consult your doctor before starting, stopping, or changing any medication. Individual results vary.
Affiliate Disclosure: CompareGLP-1 may earn a commission when you use links on this page, at no additional cost to you. Links marked "Paid link" are sponsored. Our comparisons are editorially independent — rankings and verdicts are never sold, and we never fabricate statistics, testimonials, or reviews.